AUTHOR=Jin Hyun , Jin Myung , Lim Chae Hong , Choi Joon Young , Kim Seok-Jin , Lee Kyung-Han 

TITLE=Metabolic bulk volume predicts survival in a homogeneous cohort of stage II/III diffuse large B-cell lymphoma patients undergoing R-CHOP treatment

JOURNAL=Frontiers in Oncology

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1186311

DOI=10.3389/fonc.2023.1186311

ISSN=2234-943X

ABSTRACT=<sec><title>Purpose</title><p>Accurate risk stratification can improve lymphoma management, but current volumetric <sup>18</sup>F-fluorodeoxyglucose (FDG) indicators require time-consuming segmentation of all lesions in the body. Herein, we investigated the prognostic values of readily obtainable metabolic bulk volume (MBV) and bulky lesion glycolysis (BLG) that measure the single largest lesion.</p></sec><sec><title>Methods</title><p>The study subjects were a homogeneous cohort of 242 newly diagnosed stage II or III diffuse large B-cell lymphoma (DLBCL) patients who underwent first-line R-CHOP treatment. Baseline PET/CT was retrospectively analyzed for maximum transverse diameter (MTD), total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), MBV, and BLG. Volumes were drawn using 30% SUVmax as threshold. Kaplan–Meier survival analysis and the Cox proportional hazards model assessed the ability to predict overall survival (OS) and progression-free survival (PFS).</p></sec><sec><title>Results</title><p>During a median follow-up period of 5.4 years (maximum of 12.7 years), events occurred in 85 patients, including progression, relapse, and death (65 deaths occurred at a median of 17.6 months). Receiver operating characteristic (ROC) analysis identified an optimal TMTV of 112 cm<sup>3</sup>, MBV of 88 cm<sup>3</sup>, TLG of 950, and BLG of 750 for discerning events. Patients with high MBV were more likely to have stage III disease; worse ECOG performance; higher IPI risk score; increased LDH; and high SUVmax, MTD, TMTV, TLG, and BLG. Kaplan–Meier survival analysis showed that high TMTV (<italic>p</italic> = 0.005 and &lt; 0.001), MBV (both <italic>p</italic> &lt; 0.001), TLG (<italic>p</italic> &lt; 0.001 and 0.008), and BLG (<italic>p</italic> = 0.018 and 0.049) were associated with significantly worse OS and PFS. On Cox multivariate analysis, older age (&gt; 60 years; HR, 2.74; 95% CI, 1.58–4.75; <italic>p</italic> &lt; 0.001) and high MBV (HR, 2.74; 95% CI, 1.05–6.54; <italic>p</italic> = 0.023) were independent predictors of worse OS. Older age (hazard ratio [HR], 2.90; 95% CI, 1.74–4.82; <italic>p</italic> &lt; 0.001) and high MBV (HR, 2.36; 95% CI, 1.15-6.54; <italic>p</italic> = 0.032) were also independent predictors of worse PFS. Furthermore, among subjects ≤60 years, high MBV remained the only significant independent predictor of worse OS (HR, 4.269; 95% CI, 1.03–17.76; <italic>p</italic> = 0.046) and PFS (HR, 6.047; 95% CI, 1.73–21.11; <italic>p</italic> = 0.005). Among subjects with stage III disease, only greater age (HR, 2.540; 95% CI, 1.22–5.30; <italic>p</italic> = 0.013) and high MBV (HR, 6.476; 95% CI, 1.20–31.9; <italic>p</italic> = 0.030) were significantly associated with worse OS, while greater age was the only independent predictor of worse PFS (HR, 6.145; 95% CI, 1.10–4.17; <italic>p</italic> = 0.024).</p></sec><sec><title>Conclusions</title><p>MBV easily obtained from the single largest lesion may provide a clinically useful FDG volumetric prognostic indicator in stage II/III DLBCL patients treated with R-CHOP.</p></sec>